<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00886964</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-NAT 107</org_study_id>
    <nct_id>NCT00886964</nct_id>
  </id_info>
  <brief_title>Hepatitis B Vaccination (HBV) in HIV Infected Children</brief_title>
  <official_title>Immunogenicity and Safety of Intradermal Compare to Intramuscular Hepatitis B Vaccination in HIV Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The HIV Netherlands Australia Thailand Research Collaboration</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ART AIDS Charity Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The HIV Netherlands Australia Thailand Research Collaboration</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is :&#xD;
&#xD;
        -  To evaluate prevalence of protective hepatitis B antibody comparing intradermal (ID) and&#xD;
           intramuscular (IM) route in antiHbsAb negative HIV infected children treated with highly&#xD;
           active antiretroviral therapy (HAART)&#xD;
&#xD;
        -  To revaccinate the HBV vaccine in the children who didn't have protective HBV Ab&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis B virus (HBV) and HIV share the same route of transmission and can have&#xD;
      co-infection. The prevalence of this co-infection was 8.7% in Thai adult[1, 2] and 12.1% in&#xD;
      African HIV vertically transmitted children[3]. Occurrence of HBV has effects to treatment&#xD;
      due to having the same medication, lamivudine, tenofovir, emtricitabine or entecavir, to anti&#xD;
      HIV medication. HBV can cause chronic liver disease, cirrhosis and hepatocellular carcinoma.&#xD;
&#xD;
      In Thailand, the routine HBV vaccination program was started since 1992. Few reports in&#xD;
      severe immune compromise HIV children has been shown to lose their expected preventive&#xD;
      measles and hepatitis B antibody from history of scheduled vaccination even after the immune&#xD;
      recovery by HAART[4, 5]. Limited data in of prevalence of protective hepatitis B antibody&#xD;
      response after immune recovery in Thai HIV infected children treated with highly active&#xD;
      antiretroviral therapy. In addition, HBV revaccination in this group of children should be&#xD;
      considered[6].&#xD;
&#xD;
      The response of HBV revaccination intramuscularly (IM) at 0, 2 and 6 months in 63 HIV&#xD;
      children shown response rates 17.4, 82.5, and 92.1% at 2, 6 and 7 months respectively[6].&#xD;
      Protective anti-HBs were shown in the majority of non-responders to IM HBV vaccine health&#xD;
      care workers [21/23 (91.3%)] by two doses of intradermal route (ID)[7].&#xD;
&#xD;
      We hypothesize to see the faster and higher response of antiHBs after first dose of ID&#xD;
      compare to IM in anti HBsAb negative HIV infected children. No randomized control trial&#xD;
      compare antibody response between IM and ID route in HIV children after immune recovery. The&#xD;
      benefit from this trial would be decreased the vaccine cost for resourced limited country.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of children with protective antiHBs at 8 weeks after first dose of HBV ID is superior to HBV IM</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of children with positive antiHBs at 4 weeks after second and third dose of HBV</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events in HBV ID group and HBV IM group</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of protective antiHBs in HIV children after protocol defining immune recovery</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HBV ID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HBV IM</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intradermal HBV 1 course</intervention_name>
    <description>Dosage: 2 microgram (mcg), 0.1 ml per dose&#xD;
Location: left deltoid area x 1 injection&#xD;
Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intramuscular HBV I course</intervention_name>
    <description>Dosage: 2 microgram (mcg), 0.1 ml per dose&#xD;
Location: left deltoid area x 1 injection&#xD;
Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV infected individuals&#xD;
&#xD;
          -  Age 1-18 years&#xD;
&#xD;
          -  Current CD4 within 6 months ≥ 15% or ≥ 200 cells/ml in children age ≥ 6 years&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Negative HBs Ag, antiHBs, and antiHBc at screening visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active AIDS&#xD;
&#xD;
          -  Active opportunistic infection&#xD;
&#xD;
          -  Platelet &lt; 50,000/ mm3 at screening visit&#xD;
&#xD;
          -  History of hypersensitivity to HBV vaccine&#xD;
&#xD;
          -  Using oral steroid or immunosuppressive drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torsak Bunupuradah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The HIV Netherlands Australia Thailand Research Collaboration</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HIV-NAT</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric infectious diseases section, King Chulalongkorn Memorial hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.hivnat.org</url>
    <description>HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 22, 2009</study_first_submitted>
  <study_first_submitted_qc>April 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2009</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HBV vaccine</keyword>
  <keyword>HIV children</keyword>
  <keyword>immune recovery</keyword>
  <keyword>HBV antibody</keyword>
  <keyword>Intradermal</keyword>
  <keyword>Intramuscular</keyword>
  <keyword>antibody response after HBV vaccine</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

